Pharmaceutical

CD123-targeted CAR-NK by Chongqing Precision Biotech for Natural Killer Cell Lymphomas: Likelihood of Approval

CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Natural Killer Cell Lymphomas.

Oct 3, 2023 - 20:00
CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Natural Killer Cell Lymphomas.
Read the original article

Tags:

Previous Article

MC-232 by MC2 Therapeutics for Hidradenitis Suppurativa: Likelihood of Approval

Next Article

BGB-26808 by BeiGene for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: STAT+: How to make the EU’s new Joint Clinical Assessment process work for industry — and for patients

Opinion: STAT+: How to make the EU’s new Joint Clinical...

Oct 20, 2023

Biden plans to pick Mandy Cohen to lead CDC

Biden plans to pick Mandy Cohen to lead CDC

Jun 2, 2023

Phase I completion of Sanofi’s vWD therapy demonstrates promise of pipeline

Phase I completion of Sanofi’s vWD therapy demonstrates...

May 16, 2023